ER-/PR+ Breast Cancer is Controlled More Effectively with an Inflammatory Inhibitor Than Hormonal Inhibitor

Overview

Journal Breast Cancer

Specialty Oncology

Date 2023 Mar 1

PMID 36859733

Authors

Christine Song

Ayse Tuba Kendi

Ji Yeon Shim

Dawa Jung

Pil Soo Kang

Val J Lowe

Seungbaek Lee

Affiliations

Soon will be listed here.

Abstract

Background: The anti-estrogen tamoxifen is a highly effective hormonal therapy for hormonal-positive (HR+) breast cancer patients; however, the estrogen receptor-negative, progesterone receptor-positive (ER-/PR+) subtype does not give the benefits of tamoxifen. Therefore ER-/PR+ breast cancer has a poor clinical outcome, and novel drug therapy for ER-/PR+ breast cancer could benefit these patients.

Methods: 53,805 gene expressions were characterized into HR+ BC and triple-negative breast cancer (TNBC) and analyzed through Breast Cancer Gene Expression Miner in 4319 breast cancer patient samples. The clinical outcomes including overall survival, distant metastasis-free survival, and relapse-free survival were obtained from the PrognoScan database containing 1190 human breast cancer patient samples. To determine the function of ERα and inflammation-related genes such as USP1, CDC20, and CASP1, we used the CRISPR-Cas9 system or gene knockdown (KD) system. To check tumor cell proliferation and migration of ERα KO breast cancer cell line, we used tamoxifen and the inflammation inhibitor Ac-YVAD-CHO. For further confirmation, cancer growth was checked with the inflammation inhibitor in ERα KO breast cancer cell line using a three-dimensional (3D) organoid tissue culture system (ex vivo).

Results: We found that gene expression in ER-/PR+ hormonal-positive breast cancer is positively related to ER-/PR- very similar to TNBC, not other HR+ breast cancer using a 4319 breast cancer patient database. Especially, inflammation-related genes, USP1, CDC20, and CASP1, which are highly expressed in TNBC, are also upregulated in ER-/PR+ HR+ breast cancer. Suppression of USP1, CDC20, and CASP1 inhibited tumor cell growth and metastasis in ERα KO (ER-/PR +) cell lines. Interestingly, loss of ERα in HR+ cell lines is not responsive to tamoxifen, but highly sensitive to the inflammation inhibitor, Ac-YVAD-CHO. In in vitro and ex vivo (3D organoid) models, inflammation inhibitor-specific blocks ER-/PR+ tumor proliferation and migration.

Conclusions: These findings suggest that an inflammation inhibitor might be a potential option for therapy for ER-/PR+ HR breast cancer patients.

Citing Articles

Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer.

Wu Y, Quan Y, Zhou D, Li Y, Wen X, Liu J Clin Transl Oncol. 2024; .

PMID: 39172332 DOI: 10.1007/s12094-024-03663-6.

Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via Inhibition.

Song C, Jung D, Kendi A, Rho J, Kim E, Horn I Int J Mol Sci. 2024; 25(13).

PMID: 39000600 PMC: 11242876. DOI: 10.3390/ijms25137494.

High-Resolution Profiling of Head and Neck Squamous Cells Carcinoma Identifies Specific Biomarkers and Expression Subtypes of Clinically Relevant Vulnerabilities.

Zhu Y, Peng B, Luo X, Sun W, Liu D, Li N Curr Med Chem. 2023; 31(17):2431-2448.

PMID: 37936459 DOI: 10.2174/0109298673276128231031112655.

References

Onitilo A, Engel J, Greenlee R, Mukesh B . Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009; 7(1-2):4-13. PMC: 2705275. DOI: 10.3121/cmr.2009.825. View

Carey L, Perou C, Livasy C, Dressler L, Cowan D, Conway K . Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-502. DOI: 10.1001/jama.295.21.2492. View

Dai X, Xiang L, Li T, Bai Z . Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer. 2016; 7(10):1281-94. PMC: 4934037. DOI: 10.7150/jca.13141. View

El Sayed R, Jamal L, Iskandarani S, Kort J, Abdel Salam M, Assi H . Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Front Oncol. 2019; 9:510. PMC: 6597942. DOI: 10.3389/fonc.2019.00510. View

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84. PMC: 3163848. DOI: 10.1016/S0140-6736(11)60993-8. View

Dai X, Cheng H, Bai Z, Li J . Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16):3131-3141. PMC: 5665029. DOI: 10.7150/jca.18457. View

Elledge R, Green S, Pugh R, Allred D, Clark G, Hill J . Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2001; 89(2):111-7. View

Hefti M, Hu R, Knoblauch N, Collins L, Haibe-Kains B, Tamimi R . Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013; 15(4):R68. PMC: 3978610. DOI: 10.1186/bcr3462. View

Jordan V . Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003; 2(3):205-13. DOI: 10.1038/nrd1031. View

10.

Osborne C . Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339(22):1609-18. DOI: 10.1056/NEJM199811263392207. View

11.

Ravdin P, Green S, Dorr T, McGuire W, Fabian C, PUGH R . Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992; 10(8):1284-91. DOI: 10.1200/JCO.1992.10.8.1284. View

12.

Yang L, Tseng H, Lin C, Chen L, Chen S, Kuo S . Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer. 2012; 15(3):288-95. PMC: 3468782. DOI: 10.4048/jbc.2012.15.3.288. View

13.

Bartlett J, Brookes C, Robson T, van de Velde C, Billingham L, Campbell F . Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol. 2011; 29(12):1531-8. PMC: 3082973. DOI: 10.1200/JCO.2010.30.3677. View

14.

Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C . ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer. Int J Cancer. 2021; 149(1):200-213. DOI: 10.1002/ijc.33539. View

15.

Chan M, Chang M, Gonzalez R, Lategan B, Del Barco E, Vera-Badillo F . Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS One. 2015; 10(7):e0132449. PMC: 4498889. DOI: 10.1371/journal.pone.0132449. View

16.

Ng C, Pathy N, Taib N, Mun K, Rhodes A, Yip C . The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pac J Cancer Prev. 2012; 13(4):1111-3. DOI: 10.7314/apjcp.2012.13.4.1111. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Strowig T, Henao-Mejia J, Elinav E, Flavell R . Inflammasomes in health and disease. Nature. 2012; 481(7381):278-86. DOI: 10.1038/nature10759. View

19.

Dunn J, Ellis L, Fujita M . Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 2011; 314(1):24-33. DOI: 10.1016/j.canlet.2011.10.001. View

20.

Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J . The role of pyroptosis in cancer: pro-cancer or pro-"host"?. Cell Death Dis. 2019; 10(9):650. PMC: 6733901. DOI: 10.1038/s41419-019-1883-8. View